Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non–small-cell lung cancer patients.
Cancer Network spoke with Jennie Williams, PhD, and Jenny Paredes, a PhD student, about how tumor biology impacts chemotherapy response in African American vs Caucasian patients.
Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma
Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.
Cancer Network spoke with Sheila A. Stewart, PhD, on how age-related changes in the tumor microenvironment may impact progression and metastasis.
Cancer Network spoke with Carlo Maley, PhD, about how strategies utilized in agriculture can be applied to drug resistance in oncology.
Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.
During AACR 2018, Dr. Diaz discusses the progress of his laboratory’s colorectal cancer research as part of the Stand Up 2 Cancer Colorectal Dream Team.
In this video, Dr. Melissa Davis explains how African ancestry may play a role in breast cancer, and ways that genetics might be used to help guide treatment.
In this video, Dr. Brian Schwartz highlights several small-molecule TKIs in development with the potential to help patients with several malignancies.
In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.